Question

A 59-year-old with COPD has persistent exertional dyspnea, 1 moderate exacerbation last year, eosinophils 320/µL, CAT 18. According to GOLD 2024, initial pharmacologic group and therapy?

Accepted Answer

Group E: LABA/LAMA, consider ICS if eos ≥300/µL

Answer

Group A: short-acting bronchodilator only

Answer

Group B: LABA/LAMA dual therapy

Answer

Group E: ICS monotherapy

Answer

Group B: ICS/LABA only

Practice question

A 59-year-old with COPD has persistent exertional dyspnea, 1 moderate exacerbation last year, eosinophils 320/µL, CAT 18. According to GOLD 2024, initial pharmacologic group and therapy?